Skip to content

HIV/AIDS & Alcohol-Related Outcomes: Translational Evidence-Based Interventions

HIV/AIDS & Alcohol-Related Outcomes: Translational Evidence-Based Interventions

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03238586
Acronym
WELL
Enrollment
232
Registered
2017-08-03
Start date
2012-11-30
Completion date
2019-08-31
Last updated
2020-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV/AIDS

Keywords

hiv, aids, alcohol, health, knowledge, motivation, skills, behavior

Brief summary

A clinical study for patients with HIV that investigates the best way to reduce HIV transmission risk, and to improve the overall health of people living with HIV/AIDS. Participants will complete four assessments over the course of one year and will be randomly assigned to a five-week treatment program.

Detailed description

The main purpose of this research study is to investigate the best way to reduce HIV transmission risk and to improve the overall health of people living with HIV/AIDS. This study tests an intervention program that aims to improve knowledge, motivation, and skills. The intervention program is designed to motivate participants to take their medications routinely, improve the quality of life for those living with HIV, and decrease risky behaviors that may lead to HIV transmission.

Interventions

BEHAVIORALWELL Program

Sponsors

National Institute on Alcohol Abuse and Alcoholism (NIAAA)
CollaboratorNIH
Louisiana State University Health Sciences Center in New Orleans
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* HIV positive * Recent alcohol use

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frameDescription
Viral loadChange from baseline at 3 months, 6 months and 1 yearThe primary outcome measure will be disease progression or more specifically, the proportion of patients achieving viral suppression.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026